Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CRAI and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CRAI and 80,000+ other tickers.
See exactly how CRAI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CRAI and 80,000+ other tickers.
CRA International, Inc., along with its affiliated entities, delivers specialized advisory services across the domains of economics, finance, and management in the United States, the United Kingdom, and globally. The firm provides expert guidance to clients on economic and financial considerations arising from legal disputes and regulatory challenges. Additionally, it collaborates with corporations to address matters of business strategy and operational effectiveness. Its comprehensive consulting offerings encompass in-depth research and analysis, expert witness testimony, and robust support…
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced the addition of Kevin Williams as an Academic Affiliate in the firm's Antitrust & Competition Economics Practice. “I am pleased to welcome Kevin to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Kevin is a recognized expert in the economics of industrial organization, with a focu.
Investors need to pay close attention to CRAI stock based on the movements in the options market lately.
Charles River Associates' global talent network, cross-border expertise, and rising dividends and buybacks support long-term growth and enhance investor appeal.
PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (Nasdaq: CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT.
CRAI benefits from rising demand for specialized advisory services, but AI, talent costs and fierce competition pose risks.